Uterine cancer is cancer arising in the uterus, most commonly endometrial carcinoma. It is one of the most common gynecologic malignancies and incidence has been increasing in many populations.
The FDA granted fast track designation to SIM0505, a CDH6-targeting antibody-drug conjugate, for platinum-resistant ovarian cancer based on preclinical and early clinical data. A phase 1 trial is currently evaluating the drug in advanced solid tumors, with initial data expected at the 2026 ASCO conference. The company plans to begin dose optimization studies in ovarian cancer patients in Q2 2026.
The FDA has approved labeling changes to six menopausal hormone therapy products, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia that had been in place since 2003.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07581288 |
Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression |
NOT_YET_RECRUITING | |
| NCT07542704 |
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies |
NOT_YET_RECRUITING | PHASE1 |
| NCT06904365 |
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women |
ACTIVE_NOT_RECRUITING | |
| NCT05559879 |
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma |
RECRUITING | PHASE1/PHASE2 |
| NCT03762733 |
Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies |
ENROLLING_BY_INVITATION |
